Palvella Reports Q1 Cash and Investments at $261.9M
Reports Q1 cash, cash equivalents and short-term investments were $261.9M as of March 31, 2026. Reports Q1 R&D expenses $9.3M vs $4.1M last year. Reports Q1 G&A expenses $5.5M vs $3.8M last year. "Following the positive Phase 3 SELVA topline results, we believe Palvella is on a clear path toward near-term NDA submission for QTORIN rapamycin in microcystic lymphatic malformations, with the potential for approval and U.S. commercial launch in the first half of 2027," said CEO Wes Kaupinen.
